דיגוקסין - קרן פארמה 0.25 מ"ג - Digoxin kern pharma 0.25 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | ||||||
|---|---|---|---|---|---|---|
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | C01AA Digitalis glycosides | |||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||
| צ×רת ××ª× | פ××× - PER OS | |||||
| צ×רת ××× ×× | ×××××, TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||
| ×ת×××× | Cardiac failure:Digoxin KERN PHARMA is indicated for the treatment of chronic cardiac failure where the principal cause is systolic dysfunction. The greatest therapeutic benefit is achieved in patients with ventricular dilatation.Digoxin KERN PHARMA is specifically indicated where cardiac failure is accompanied by atrial fibrilation.Supraventricular arrhythmias:Digoxin KERN PHARMA is indicated for the treatment of certain supraventricular arrhythmias, particularly atrial fibrillation and flutter, where its principal beneficial effect is to reduce the ventricular rate.
| |||||
× ×ª×× × ×¡× [ ×צ×× ]
| ||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | |||||
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| ××××קס×× - ×§×¨× ×¤×ר×× 0.25 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | KERN PHARMA S.L, SPAIN |
| ×©× ××¢× ×ר×ש×× | TRIMA ISRAEL PHARMACEUTICAL PRODUCTS MAABAROT LTD |
| ר×ש××× | ת×ר×× ××ש×: 04/2013. ר×ש××× ×ת×ר××: 12/2018 |
| ת×ר×× ×¢×××× ××ר×× | 14/05/19 |